Minerva Neurosciences (NERV) FDA Approvals $3.40 -0.05 (-1.45%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.40 0.00 (0.00%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest Minerva Neurosciences' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Minerva Neurosciences (NERV). Over the past two years, Minerva Neurosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Roluperidone. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Roluperidone (MIN-101) FDA Regulatory Events Roluperidone (MIN-101) is a drug developed by Minerva Neurosciences for the following indication: Schizophrenia. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 31,2026Provided Update Phase 3Drug: Roluperidone (MIN-101)Announced Date: March 31, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia.AI SummaryMinerva Neurosciences announced that the first patient has been screened in its global, confirmatory Phase 3 trial testing roluperidone as a single (monotherapy) treatment for negative symptoms of schizophrenia. Negative symptoms—such as avolition (severe lack of motivation), anhedonia (inability to feel pleasure), and social withdrawal—can cause major personal and functional problems and are considered one of the biggest unmet needs in schizophrenia care. Roluperidone has shown consistent positive results in two prior pivotal trials, which the company says reduces development risk. It remains the only late-stage drug candidate focused specifically on this high-need patient group. The ongoing Phase 3 study aims to confirm those earlier findings, and Minerva expects to report efficacy topline data in the second half of 2027. If successful, roluperidone could offer a new option for patients whose negative symptoms are not helped by current treatments.Read AnnouncementData Presentation - March 25,2026Data Presentation Drug: Roluperidone (MIN-101)Announced Date: March 25, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.AI SummaryMinerva Neurosciences announced that it presented clinical data from an open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026 in Florence, Italy. The presentation covered safety findings and trial details for clinicians and researchers attending the meeting. The trial demonstrated no safety concerns when roluperidone was given alongside olanzapine. Minerva said it is continuing to advance the program and has a confirmatory Phase 3 trial now enrolling. The company expects topline Phase 3 data in the second half of 2027, which would be an important milestone for evaluating the therapy’s effectiveness and broader safety profile. The presentation will be posted after the conference on Minerva’s website under the Presentations section at: https://tinyurl.com/MinervaPresentations.Read Announcement Minerva Neurosciences FDA Events - Frequently Asked Questions Has Minerva Neurosciences received FDA approval? As of now, Minerva Neurosciences (NERV) has not received any FDA approvals for its therapy in the last two years. What drugs has Minerva Neurosciences submitted to the FDA? In the past two years, Minerva Neurosciences (NERV) has reported FDA regulatory activity for Roluperidone (MIN-101). What is the most recent FDA event for Minerva Neurosciences? The most recent FDA-related event for Minerva Neurosciences occurred on March 31, 2026, involving Roluperidone (MIN-101). The update was categorized as "Provided Update," with the company reporting: "Minerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia." What conditions do Minerva Neurosciences' current drugs treat? Currently, Minerva Neurosciences has one therapy (Roluperidone (MIN-101)) targeting the following condition: Schizophrenia. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events C4 Therapeutics FDA EventsLegend Biotech FDA EventsOcugen FDA EventsBristol Myers Squibb FDA EventsJohnson & Johnson FDA EventsMerck & Co., Inc. FDA EventsACADIA Pharmaceuticals FDA EventsAnnexon FDA EventsBioLineRx FDA EventsEnsysce Biosciences FDA EventsLakewood-Amedex Biotherapeutics FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsMesoblast FDA EventsMediciNova FDA EventsSatellos Bioscience FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies CorMedix FDA Events Phathom Pharmaceuticals FDA Events Aquestive Therapeutics FDA Events Bright Minds Biosciences FDA Events Ovid Therapeutics FDA Events Assembly Biosciences FDA Events Contineum Therapeutics FDA Events Turn Therapeutics FDA Events Relmada Therapeutics FDA Events Atea Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:NERV last updated on 4/1/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 31,2026Provided Update Phase 3Drug: Roluperidone (MIN-101)Announced Date: March 31, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia.AI SummaryMinerva Neurosciences announced that the first patient has been screened in its global, confirmatory Phase 3 trial testing roluperidone as a single (monotherapy) treatment for negative symptoms of schizophrenia. Negative symptoms—such as avolition (severe lack of motivation), anhedonia (inability to feel pleasure), and social withdrawal—can cause major personal and functional problems and are considered one of the biggest unmet needs in schizophrenia care. Roluperidone has shown consistent positive results in two prior pivotal trials, which the company says reduces development risk. It remains the only late-stage drug candidate focused specifically on this high-need patient group. The ongoing Phase 3 study aims to confirm those earlier findings, and Minerva expects to report efficacy topline data in the second half of 2027. If successful, roluperidone could offer a new option for patients whose negative symptoms are not helped by current treatments.Read Announcement
Data Presentation - March 25,2026Data Presentation Drug: Roluperidone (MIN-101)Announced Date: March 25, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.AI SummaryMinerva Neurosciences announced that it presented clinical data from an open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026 in Florence, Italy. The presentation covered safety findings and trial details for clinicians and researchers attending the meeting. The trial demonstrated no safety concerns when roluperidone was given alongside olanzapine. Minerva said it is continuing to advance the program and has a confirmatory Phase 3 trial now enrolling. The company expects topline Phase 3 data in the second half of 2027, which would be an important milestone for evaluating the therapy’s effectiveness and broader safety profile. The presentation will be posted after the conference on Minerva’s website under the Presentations section at: https://tinyurl.com/MinervaPresentations.Read Announcement
